Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — FY2023 Earnings Presentation
44 slides from Aspen Pharmacare's earnings presentation, Aug 31, 2023
Slide 1: FY 2023 Annual Results
») ti FY 2023 ANNUAL RESULTS 31 AUGUST 2023 Healthoare wecare © aspen
Slide 2: Disclaimer
DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.
Slide 3: Performance Review
DE. PERFORMANCE REVIEW Healthcare. We Care. 6) aspen tnt rn nnn n nt NN SSNs nus 0 0000000000000
Slide 4: Highlights from FY 2023 Operational Performance
HIGHLIGHTS FROM FY 2023 OPERATIONAL PERFORMANCE MEETING EBITDA GUIDANCE GUIDANCE FY 2023 EBITDA to align with prior year’s performance at R11bn Needed a record H2, as » In H1, EBITDA ↓ 11% on revenue also ↓ on prior year Material EBITDA losses relative to the prior year included: » COVID vacci
Slide 5: FY 2023 Operational Performance Highlights
FY 2023 OPERATIONAL PERFORMANCE HIGHLIGHTS RECORD SECOND HALF DELIVERY We achieved R21bn in sales, which represents our highest-ever achievement of H2 sales » Normalised EBITDA for H2 was also a record over R6.6bn H2 2023 vs H2 2022 reported revenue » Commercial Pharma +11% » Regional brands +9% » S
Slide 6: Group Revenue
GROUP REVENUE % change R'million FY 2023 FY 2022 Reported CERǂ Commercial Pharma 29 412 27 658 6% -1% Regional Brands 18 824 17 405 8% 1% Sterile Focus Brands 10 588 10 253 3% -6% Manufacturing 11 297 10 948 3% -6% Group revenue 40 709 38 606 5% -3% Excluding impact of prior year divestment of R1.
Slide 7: Commercial Pharma | Regional Brands
COMMERCIAL PHARMA | REGIONAL BRANDS REVENUE % change R’million FY 2023 FY 2022 Reported CERǂ Africa Middle East 7 711 7 878 -2% -3% Australasia 5 150 4 464 15% 7% Americas 3 452 2 856 21% 2% Europe CIS 1 774 1 594 11% 2% Asia 737 613 20% 9% Regional Brands 18 824 17 405 8% 1% Growth momentum achie
Slide 8: Commercial Pharma | Steriles
COMMERCIAL PHARMA | STERILES REVENUE % change R’million FY 2023 FY 2022 Reported CERǂ Asia 4 768 4 503 6% -3% Europe CIS 3 073 3 143 -2% -11% Americas 1 627 1 439 13% -2% Australasia 677 643 5% -3% Africa Middle East 443 525 -16% -18% Sterile Focus Brands 10 588 10 253 3% -6% Strong rebound from H
Slide 9: Manufacturing
MANUFACTURING REVENUE % change R’million FY 2023 FY 2022 Reported CERǂ API 5 024 4 894 3% -6% Heparin 3 423 2 379 44% 33% FDF - Steriles 1 480 2 567 -42% -47% FDF - Other 1 370 1 108 24% 13% Manufacturing 11 297 10 948 3% -6% Manufacturing in H2 grew 15% (+0% CER) H1 reported revenue -10% (-12%
Slide 10: Financial Review
FINANCIAL REVIEW Healthcare. We Care. © aspen nnn 00 000000
Slide 11: Financial Highlights
FINANCIAL HIGHLIGHTS RECORD H2 REBOUND ON REVENUE AND EBITDA AS GUIDED INCREASED NET FINANCE COSTS REDUCES NHEPS GROWTH BY 141 CENTS (-9%) -3% CERⱡ -6% CERⱡ -15% CERⱡ +5% +1% -8% 1 628 40 709 11 100 11 012 1 499 38 606 +13% +18% +20% 21 559 6 017 19 150 819 5 083 680 FY 2022 H1 2023 H2 2023 FY 2023
Slide 12: Financial Highlights
FINANCIAL HIGHLIGHTS 5% INCREASE IN DIVIDEND DECLARED SUPPORTED BY IMPROVED OPERATING CASH FLOW +5% -1% +9% +5% 1 243 FX 18.6 88% 1 186 18.4 342 326 81% 1.9X 1.9X 16.1 FY 2022 FY2023 FY 2022 FY2023 FY 2022 FY2023 FY 2022 FY2023 Net Borrowings (CER) ⱡ Operating cash flow per Operating cash Dividend p
Slide 13: Financial Highlights
FINANCIAL HIGHLIGHTS HIGHEST REPORTED H2 REVENUE & NORMALISED EBITDA FROM CONTINUING OPERATIONS 21 559 19 225 19 133 17 690 15 211 H2 2023 revenue up +12% on H2 2022 » Commercial Pharma revenue up +11% » Manufacturing revenue up +15% Currency tailwinds are a big factor On a CER basis, revenue
Slide 14: Gross Profit Percentage
GROSS PROFIT PERCENTAGE | CERǂ AT YTD JUNE 2023 RATES RESILIENT AND IMPROVING COMMERCIAL PHARMA GROSS PROFIT MARGINS Regional Brands Sterile Focus Brands 59.7% 59.6% 59.6% 60.8% 60.6% 60.5% 60.0% 56.5% Favourable sales mix and cost Site transfer savings improve of goods savings more than FY 2023 tre
Slide 15: Normalised EBITDA
NORMALISED EBITDA REPORTED EBITDA IN LINE WITH FY 2022 AS GUIDED R'million FY 2023 % of revenue FY 2022 % of revenue % change % change CERǂ Revenue 40 709 100.0% 38 606 100.0% 5% -3% Gross profit* 18 934 46.5% 18 306 47.4% 3% -4% Depreciation 1 247 3.1% 1 167 3.0% 7% 0% Operating expenses (9 426) 23
Slide 16: Net Financing Costs
NET FINANCING COSTS SIGNIFICANT FOREX LOSSES IN A VOLATILE MARKET EM currencies against EUR: 2023 R’million FY 2023 H2 2023 H1 2023 FY 2022 2 1.9 Net interest paid (591) (338) (253) (468) 1.8 1.7 1.6 Effective interest rate for the 1.5 3.21% 3.55% 2.83% 2.92% 1.4 period* 1.3 1.2 1.1 Foreign exchange
Slide 17: Working Capital
WORKING CAPITAL INCREASED HEPARIN INVESTMENT TO SUPPORT VIATRIS LATAM TRANSACTION Operating cash conversion cycle +11% Cash out flow 250% +R3 358m 200% 201% 2 701 657 -1 165 150% 22 210 922 Commercial Pharma 117% 115% 100% Heparin 1 064 50% 50% 58% 20 017 715 Other Manufacturing 0% H2 2021 H1 2022 H
Slide 18: Delivering on Our ESG Commitments
DELIVERING ON OUR ESG COMMITMENTS » Access to affordable high-quality medicines across a broad geography including more than 60 low- and middle- Patient income countries » Progression against milestones in strategic position paper on access to medicines^ » Technical transfer of 4 vaccines from The S
Slide 19: Strategic Review
STRATEGIC REVIEW veaimone ecw @ aspen ttn ttt nnn U NN rnttttttssttttssttstt0000t0sstss 0s stuusnnnn
Slide 20: Core Strategic Commercial Objectives
CORE STRATEGIC COMMERCIAL OBJECTIVES THE BIG FIVE Commercial Pharma Manufacturing Drive organic growth Contracts closed to be converted into material » Commercial Pharma has performed in spite of contributors to the Group no capital allocated over last 4 years » Have built a relevant globally si
Slide 21: Commercial Pharma | Incremental Growth Drivers
COMMERCIAL PHARMA | INCREMENTAL GROWTH DRIVERS SOUTH AFRICA | BENEFIT OF FOOTPRINT SA Commercial business has a respected, professional and capable footprint across Southern Africa Partnering with multinationals provides mutual benefits by significantly outperforming a small standalone local entity
Slide 22: Commercial Pharma | Growth Drivers
COMMERCIAL PHARMA | GROWTH DRIVERS LATAM OPPORTUNITY | BUILDING THE FOOTPRINT Team rewarded for sustained performance Double digit CAGR growth over past 7 years Key household brands bolted-on to region with demonstrated capability Growing, post-patent/lifestyle brands with loyal support Line e
Slide 23: Commercial Pharma | China Strategy
COMMERCIAL PHARMA CHINA | STRATEGY FOR FUTURE FOOTPRINT Potential to be the largest by Last material wrinkle in Numerous other companies Aspen is in advanced country value in Aspen Commercial Pharma also impacted by VBP negotiations on some exciting opportunities » Expected in the short to » Project
Slide 24: Manufacturing | 2024 Background
MANUFACTURING 2024 BACKGROUND API business Business has rebounded and approaching pre-COVID levels Business rebound to be sustained Heparin Anticipate strong downward pricing adjustments in raw materials and pricing, will drive down selling prices Certainty through committed Viatris offtake
Slide 25: Manufacturing | Sterile Manufacturing Agreements
MANUFACTURING STERILE MANUFACTURING AGREEMENTS South Africa Insulin franchise for major multinational » Material global volumes including Africa Serum Institute » Focus on Gavi volumes for Africa Further material volumes for both France and SA under discussion France Three agreements signed wi
Slide 26: Manufacturing | Guidance
MANUFACTURING GUIDANCE At the half year we guided R2bn of contribution for CY 2024 and R4bn for CY 2025 Contribution conversion of at least 70% to EBITDA This guidance is maintained Working positively to grow this base with additional contracted volumes For FY 2024 we expect gross margin in Ma
Slide 27: Summary and Prospects
SUMMARY AND PROSPECTS FY 2024 PERFORMANCE Aspen has strong short to medium growth prospects OUTLOOK » For both Commercial Pharma and Manufacturing COMMERCIAL Double digit growth in reported revenue^ PHARMA » Driven by organic growth » Recent transactions in Latam and Sub-Saharan Africa » China t
Slide 28: Guidance and Prospects | H2 2024 Inflection Point
GUIDANCE AND PROSPECTS H2 2024 | THE INFLECTION POINT FY 2024 Growth for FY 2024 projected » Led by double digit reported revenue growth from Commercial Pharma » Results heavily weighted to H2 H1 2024 H1 - in line with prior year reported results » China VBP impacts » Prior year had grants H2 20
Slide 29: Appendices
2=... APPENDICES | Healthcare. We Care. 6) aspen
Slide 30: Abridged Statement of Comprehensive Income
APPENDIX 1 | ABRIDGED STATEMENT OF COMPREHENSIVE INCOME R’million FY 2023 FY 2022 % change H1 2023 Net revenue 40 709 38 606 5% 19 150 Cost of sales (21 775) (20 300) (10 184) Gross profit 18 934 18 306 3% 8 966 Gross profit margin 46.5% 47.4% 46.8% Operating expenses (9 426) (8 539) (4 621) Other o
Slide 31: Abridged Statement of Normalised Comprehensive Income
APPENDIX 2 | ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME R’million FY 2023 FY 2022 % change FY 2022 (CERǂ) % change (CERǂ) H1 2023 Net revenue 40 709 38 606 5% 41 817 -3% 19 150 Cost of sales (21 775) (20 300) 7% (22 092) -1% (10 184) Gross profit 18 934 18 306 3% 19 725 -4% 8 966 Gross pr
Slide 32: Reconciliation of Reported to Normalised EBITDA
APPENDIX 3 | RECONCILIATION OF REPORTED TO NORMALISED EBITDA R’million FY 2023 FY 2022 % change H1 2023 Net revenue 40 709 38 606 5% 19 150 Cost of sales (21 775) (20 300) (10 184) Gross profit 18 934 18 306 3% 8 966 Operating expenses (9 426) (8 539) (4 621) Other operating expenses (2 382) (3 046)
Slide 33: Reconciliation of NHEPS
APPENDIX 4 | RECONCILIATION OF NHEPS FY 2022 % change Cents FY 2023 FY 2022 % change H1 2023 (CERǂ) (CERǂ) Basic earnings per share (EPS) 1 176.9 1 432.3 -18% 1 523.1 -23% 602.0 Impairment of property, plant and equipment 0.7 1.9 1.9 - Impairment of intangible assets 292.0 327.3 348.0 59.3 Impairmen
Slide 34: Normalised Headline Earnings Bridge
APPENDIX 5 | NORMALISED HEADLINE EARNINGS BRIDGE FOREX LOSSES DILUTE NHEPS -10% -16% -R715m -R1 288m 7 946 573 NHEPS = 1499 cents -744 NHEPS decline = -10% 7 373 Share buy-back benefited NHEPS by +2% 5 48 -633 6 657 -99 134 FY 2022 Fx impact FY 2022 CER ǂ Normalised Depreciation Amortisation Forex N
Slide 35: Currency Mix
APPENDIX 6 | CURRENCY MIX SIGNIFICANT EMERGING MARKET CURRENCY VOLATILITY IN FY 2023 FY 2023 FY 2022 Currency Normalised Normalised FY 2023 FY 2022 contribution Revenue EBITDA Revenue EBITDA average rate average rate % change EUR 30% 17% 31% 22% 18.61 17.14 9% ZAR 15% 9% 17% 11% AUD 15% 22% 14% 18%
Slide 36: Net Working Capital
APPENDIX 7 | NET WORKING CAPITAL LOWER WORKING CAPITAL CASH OUTLFOW IN H2 2023 3% Cash outflow +R1 157m 5 320 650 832 415 22 210 326 Commercial Pharma 258 Heparin 21 468 248 Other manufacturing 1 910 19 558 H1 2023 Fx impact H1 2023 CERǂ Inventory Trade Trade payables Net other Non cash FY 2023 Repo
Slide 37: Effective Tax Rates
APPENDIX 8 | EFFECTIVE TAX RATES INCREASED NORMALISED EFFECTIVE TAX RATE IN FY 2023 24.0% 22.0% 19.9% 20.2% 20.2% 20.0% 17.6% 18.0% 16.9% 16.4% 16.0% 14.0% 12.0% 10.0% FY 2021 FY 2022 FY 2023 Group effective tax rate Group normalised effective tax rate Increase in normalised effective tax rate in
Slide 38: Operating Cash Flows
APPENDIX 9 | OPERATING CASH FLOWS OPERATING CASH CONVERSION RATE IN H2 2023 OF 115% FY 2023 FY 2022 % change H1 2023 Cash operating profit 11 300 10 023 13% 5 312 Changes in working capital (3 358) (2 652) -27% (2 168) Cash generated from operations 7 942 7 371 8% 3 144 Net finance costs paid (808)
Slide 39: Capital Expenditure
APPENDIX 10 | CAPITAL EXPENDITURE STERILE CAPEX EXPANSION PROJECT ON TRACK 2 300 2 230 1 963 PPE Capex 700 818 1 700 Sterile expansion project plan in South Africa is progressing to plan and is 500 well poised to take advantage of new third party manufacturing opportunities Planned Capex expecte
Slide 40: Net Financing Costs
APPENDIX 11 | NET FINANCING COSTS RECONCILIATION OF NORMALISED TO REPORTED NET FINANCING COSTS R’million FY 2023 H2 2023 H1 2023 FY 2022 Net interest paid (591) (338) (253) (468) Effective interest rate for the period* 3.21% 3.55% 2.83% 2.92% Foreign exchange (losses)/gain (434) (200) (234) 184 Noti
Slide 41: Net Borrowings
APPENDIX 12 | NET BORROWINGS WELL BALANCED BORROWINGS REPAYMENT PROFILE 18.370 18.751 At 30 June 2022, Aspen had in place syndicated debt facilities 4.827 7.907 totaling the equivalent of R17,1 billion which were due to mature on 16.064 1 July 2023 (the “Maturing Facilities”). R8,4 billion of the
Slide 42: Net Borrowings Bridge
APPENDIX 13 | NET BORROWINGS BRIDGE WEAKER ZAR INCREASES REPORTED NET BORROWINGS. 1% REDUCTION IN CERǂ BORROWINGS -1% 18 609 18 370 Leverage ratio well below targeted levels at 1.9x 1 455 2 545 16 064 -5 520 3 181 309 336 FY 2022 Fx impact FY 2023 CERǂ Cash flows Other Deferred PPE and IP spend Divi
Slide 43: Prior Year Transactions
APPENDIX 14 | PRIOR YEAR TRANSACTIONS DEFERRED CONSIDERATION PAYMENTS R'million FY 2023 Disposal of the European Thrombosis assets – volume incentive payments and other transaction costs (441) Disposal of Japanese business – supply rebate payments (134) Disposal of Japanese business – uninterrupted
Slide 44: Capital Allocation
APPENDIX 15 | CAPITAL ALLOCATION 1 PPE capex and IP development 2 Bolt-on acquisitions & disposals of IP & businesses * 3 Dividend paid 4 Larger acquisitions & disposals R3 181 million R309 million No significant R1 455 million invested net outflow outflow Ensure business Inherent to renewal of Divi
Aspen Pharmacare Holdings — FY2023 Earnings Presentation on 6ix